In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Martin Griesshammer outlines his view on the current and future use of JAK inhibitors for essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).
Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology
Also Recommended: Myelofibrosis Danazol vs Momelotinib a JAK inhibitor
Advertisement
© 2017 Imedex, LLC.